GlaxoSmithKline

GSK's Phase III AReSVi-006 trial of Arexvy RSV vaccine showed 62.9% cumulative efficacy against RSV-LRTD over three seasons, with 67.4% against severe cases. The vaccine maintained 48% efficacy in the third season and demonstrated safety consistent with prior data.

GSK and Pfizer see US RSV vaccine sales decline; Sage discontinues Alzheimer’s drug post late-stage trial failure.

GSK's Arexvy vaccine showed 63% efficacy against RSV over three seasons, with a decline to 48% in the third season. The CDC does not recommend a second dose, but GSK suggests revaccination may be needed. Arexvy is the only RSV vaccine with three-season data, and GSK will provide further data to help determine future schedules.

Article references highlight studies on risk of bias in in vivo research, comparison of treatment effects between animal experiments and clinical trials, validation of therapeutic targets through human genetics, and the decline in pharmaceutical R&D efficiency. Key topics include Mendelian randomization for drug target validation, clinical development success rates, and the use of genetic evidence in drug approval. The article also mentions the integration of genetic data into electronic health records and the potential of RNA-based therapeutics.

PDF document structure and metadata details, including page, catalog, and viewer preferences.

GSK's AReSVi-006 phase III trial shows Arexvy vaccine's cumulative efficacy at 62.9% against RSV-LRTD and 67.4% against severe RSV-LRTD over three RSV seasons in adults aged 60+.

GSK's RSV vaccine, Arexvy, shows cumulative efficacy of 62.9% against RSV-LRTD and 67.4% against severe RSV-LRTD over three RSV seasons in adults aged 60 and older, including those at increased risk. Safety data aligns with previous results, and GSK will continue to provide long-term follow-up data to inform future revaccination schedules.

New RSV vaccines for older adults, infants, and pregnant women offer protection against severe RSV, which can be life-threatening for high-risk groups. Vaccines include ABRYSVO®, AREXVY®, and mRESVIA® for adults, nirsevimab for infants, and ABRYSVO for pregnant women to protect newborns.

New human H5 influenza cases in California, Marburg vaccine trial in Rwanda, and chem-bio AI model safety considerations.